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Abstract
An emerging strategy for the treatment of monogenic diseases uses genetic engineering to 
precisely correct the mutation(s) at the genome level. Recent advancements in this technology 
have demonstrated therapeutic levels of gene correction using a zinc-finger nuclease (ZFN)-
induced DNA double-strand break in conjunction with an exogenous DNA donor substrate. This 
strategy requires efficient nucleic acid delivery and among viral vectors, recombinant adeno-
associated virus (rAAV) has demonstrated clinical success without pathology. However, a major 
limitation of rAAV is the small DNA packaging capacity and to date, the use of rAAV for ZFN 
gene delivery has yet to be reported. Theoretically, an ideal situation is to deliver both ZFNs and 
the repair substrate in a single vector to avoid inefficient gene targeting and unwanted 
mutagenesis, both complications of a rAAV co-transduction strategy. Therefore, a rAAV format 
was generated in which a single polypeptide encodes the ZFN monomers connected by a ribosome 
skipping 2A peptide and furin cleavage sequence. On the basis of this arrangement, a DNA repair 
substrate of 750 nucleotides was also included in this vector. Efficient polypeptide processing to 
discrete ZFNs is demonstrated, as well as the ability of this single vector format to stimulate 
efficient gene targeting in a human cell line and mouse model derived fibroblasts. Additionally, we 
increased rAAV-mediated gene correction up to sixfold using a combination of Food and Drug 
Administration-approved drugs, which act at the level of AAV vector transduction. Collectively, 
these experiments demonstrate the ability to deliver ZFNs and a repair substrate by a single AAV 
vector and offer insights for the optimization of rAAV-mediated gene correction using drug 
therapy.
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 INTRODUCTION
Gene therapy is fundamentally aimed at using nucleic acids as reagents to alter cellular 
behavior and thereby cure disease. The recognition that the phenotype of cells could be 
readily altered by the introduction of new DNA fragments, made the prospect of gene 
therapy seem feasible. Over the last several decades, significant work has been invested in 
translating this research tool into clinical benefit for patients with monogenic diseases as 
disparate as severe combined immunodeficiency,1 adenosine deaminase deficiency,2 
Wiskot--Aldrich syndrome3 and Leber’s congenital amaurosis.4 Such experiments rely on 
gene addition approaches in which the therapeutic cDNA is expressed from a non-native 
promoter and is maintained extrachromosomal or integrated into a random chromosomal 
site. An emerging strategy is to correct the mutant gene at the endogenous locus via 
homologous recombination, which preserves the integrity/regulation imparted by the native 
locus (herein referred to as gene targeting).
The spontaneous frequency of gene targeting using plasmid vectors is on the order of 10−6, a 
frequency too low to translate to clinical use.5,6 However, reports demonstrate that sequence-
specific endonucleases can increase the efficiency of gene targeting by 100–50 000-fold,7–13 
a frequency that has clinical relevance to a variety of diseases. Currently, there are three 
major classes of nucleases that can be used to create sequence-specific DNA double-strand 
breaks (DSBs): homing endonucleases, TALE nucleases and zinc-finger nucleases 
(ZFNs).14–17 In particular, ZFNs are engineered proteins that fuse zinc finger DNA-binding 
domains to a C-terminal nuclease domain derived from the type IIS FokI restriction 
endonuclease.18 A pair of ZFNs bind their cognate recognition sites in a specific orientation 
thereby allowing the nuclease domain to dimerize and enzymatically create the DNA DSB. 
Theoretically, a pair of ZFNs can be designed to bind and cleave nearly any site in the 
human genome including sites of mutated genes that cause disease. Practically, ZFNs have 
been engineered to a wide range of gene targets and have been shown to stimulate specific 
gene modification in a wide range of cell types.19 –24
Despite the ‘hit and run’ nature of nuclease-mediated genome modification, the issue of how 
to introduce the components necessary for gene targeting (the nuclease and donor fragment) 
remains a challenge, particularly in cell types that are transfected at low efficiency. 
Moreover, if one were to consider using gene targeting for in vivo therapy, physical, 
chemical and electrical means of transfection are currently not practically viable options. 
The use of non-integrating viral vectors for delivery of the gene targeting components is one 
strategy to overcome the barrier of inefficient transfection. Lombardo et al.22 have 
demonstrated that integration-defective lentivirus can be an effective method to deliver the 
gene targeting components as they demonstrated high frequencies of gene targeting in a 
range of human cell types. A potential alternative to integration-defective lentivirus, is the 
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use of recombinant adeno-associated virus (rAAV) for delivery, which demonstrates 
enhanced transduction in vitro and in vivo and is currently used in human trials.
rAAV capsids are packaged with a single-strand DNA molecule <5 kb containing transgenic 
DNA flanked by the viral inverted terminal repeats. The most widely studied serotype is 
AAV2, but currently there are well over 10 natural described serotypes, with hundreds of 
variants, which have a broad tropism to transduce dividing or non-dividing cell types both ex 
vivo and in vivo.25,26 One of the fascinating, and still not fully explained, properties of 
rAAV is that high efficiencies of gene targeting (up to 1%) have been reported without the 
induction of a gene-specific DSB using rAAV DNA as the repair substrate.27 In addition, 
rAAV has been shown to be an effective method of delivery to stimulate gene targeting using 
homing endonucleases. Both Miller et al.28 and Porteus et al.29 demonstrated that rAAV2 
could be used to deliver the homing endonuclease I-SceI and the donor fragment via co-
transduction in human cell lines to stimulate high frequencies of gene targeting (>1%). 
Recently, it was shown that using I-SceI in a different gene targeting system, in different 
cells (U2OS), could produce targeting frequencies up to 65% using rAAV2 for delivery.30 It 
was also recently reported that gene targeting was stimulated in cells provided with ZFNs 
linked by a 2A peptide by plasmid transfections.31,32
In this work, we show that high frequencies of gene targeting (~1%) can be achieved in a 
human cell line and in mouse model derived fibroblasts using a single AAV6 vector for 
delivery of both ZFNs and a repair substrate. To do this we demonstrated efficient 
polypeptide cleavage to discrete ZFNs using a previously described 2A peptide and furin 
cleavage sequence in a rAAV context.33 This genetic arrangement accommodated a 750 
nucleotide DNA repair substrate for a total vector size at the AAV packaging capacity of 4.7 
kb. Experiments using a supplementary donor vector suggest that the repair substrate is 
limiting to a point, at which the efficiency decreases, presumably due to vector transduction 
competition. Finally, we show that the frequency of gene targeting mediated by rAAV6 
transduction, but not plasmid transfection, can be increased by proteasome or histone 
deacetylase (HDAC) inhibitors. Additionally, an additive effect on gene targeting is observed 
when cells are treated with both drug regimens.
 RESULTS
Initially, we created two AAV plasmids for these experiments investigating ZFN-induced 
gene targeting by rAAV vectors (Figures 1a and b). The first, ‘ZFN2/1/donor’, contains an 
expression cassette for green fluorescent protein (GFP)-ZFN1 and GFP-ZFN2(refs 20,34) 
driven by the human ubiquitin C promoter (UBC) in which the two ZFNs are linked by a 2A 
peptide sequence and a furin cleavage site.33 In addition, this vector contains an ~750 base 
pair eGFP DNA fragment (truncated to eGFP nucleotide 37; Figure 1 ‘donor’), 5′ of the 
BgH poly-adenylation sequence, that serves as the donor template for the homologous 
recombination machinery to correct our previously described defective GFP reporter 
system.5 The final vector size is ~4.7 kb, which is about the size of the wild-type AAV 
genome. In addition to this ZFN2/1donor vector, we also created an AAV construct 
containing only the repair substrate (donor; Figure 1b).
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The ZFN co-synthesis peptide cleavage system should allow for production of two ZFNs 
from a single polypeptide, thus poly-peptide cleavage into discrete ZFNs was investigated by 
western blotting (Figure 1c). Transfection of two different viral vector plasmids containing 
the ZFN expression cassette demonstrated that the ZFNs were efficiently processed into 
monomeric units, while no unprocessed molecules were observed (Figure 1b). Next, we 
produced rAAV particles harboring the described ZFN +donor genome. AAV serotype 6 was 
used in these experiments as we found in general, this capsid is most efficient for primary 
cell transduction (Ellis et al., submitted). We then investigated the ability of the produced 
rAAV6 particles to stimulate gene targeting in two different cell types. The first is a human 
HEK 293 cell line ‘293/GFP*’ that contains a single chromosomal integrated copy of a 
mutated GFP gene.5 The other cell type investigated herein is a primary mouse fibroblast, 
immortalized by using the standard NIH 3T3 protocol, which contains the same defective 
GFP gene correction reporter integrated into the ROSA26 locus.20 We chose to use mouse 
fibroblasts that are heterozygous for the mutated GFP transgene cassette (GFP*) to allow a 
better comparison of targeting with our single copy 293 integrant line (theoretically the same 
copy number of the GFP* reporter). In these systems, gene targeting results in the correction 
of a small insertion in the integrated GFP* gene and converts the cell from being 
phenotypically GFP negative to GFP positive. The frequency of correction can then be 
quantitated by flow cytometry.
Initially, we infected the 293/GFP* cells with increasing amounts of rAAV6-ZFN2/1/donor 
and found a dose-dependent increase in gene targeting up to 0.91% (Figure 2a) at a 
multiplicity of infection (MOI) of 500 000 vector genomes per cell ‘500K’. Although, this 
MOI seems extremely high, it is important to note these particles use the AAV6 capsid, 
which is 5–10-fold deficient for transduction on this cell type compared with AAV2. Control 
experiments demonstrated that ZFN expression in the absence of the repair substrate, or the 
repair substrate alone, does not produce GFP-positive cells, which we consistently see using 
these ZFNs and the GFP* reporter model5,29 (Supplementary Figure S1). Previously, we 
have found by transfection that targeting frequencies can diminish with excessive ZFN 
expression and with limiting DNA donor fragment amounts.35 Here, we found that if we fix 
the MOI of rAAV6 ZFN2/1/donor at 300K and supplement the infection with increasing 
amounts of the rAAV6 donor virus (an MOI from 50 to 500K), we increased the frequency 
of gene targeting several fold to ~3% of treated cells (Figure 2b). Importantly, we performed 
this experiment in the presence of donor virus alone at increasing concentrations and did not 
observe a single gene targeting event in over 100 000 analyzed cells, again providing 
evidence of the necessity of a DNA DSB to stimulate gene targeting (Figure 1b, 
Supplementary Figure S1). In this particular experiment the targeting frequency is higher 
than that achieved by transfection, however, it is comparable to what we routinely achieve by 
transfection in other experiments in this cell line (Figures 2a and b, data not shown). Thus, 
supplementing rAAV6 ZFN2/1/donor transduction with rAAV6 donor vectors resulted in 
increased gene targeting to a point, then the efficiency decreased thereafter, possibility as a 
result of transduction competition of the ZFN2/1/donor and donor only vectors.
To determine the toxicity of rAAV6-mediated ZFN-stimulated gene targeting, we performed 
a time course in which the percentage of GFP-positive cells was determined over time 
(Figures 2c and d). When high MOIs of the rAAV6 ZFN2/1/donor virus were used, there 
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was a greater fall in the number of GFP-positive cells over time, suggesting greater toxicity 
(Figure 2c). We also examined the persistence of GFP-positive cells over time with an MOI 
of 100 and 200K and found the same trend (data not shown). A similar drop in the 
percentage of GFP-positive cells was observed after transfection, suggesting that the toxicity 
was not entirely the result of rAAV6 infection. We examined the persistence of GFP-positive 
cells when we supplemented rAAV6 ZFN2/1/donor with rAAV6 donor and found a similar 
decrease in GFP-positive cells over time (Figure 2d). The maximal targeting efficiency was 
achieved, however, at both short and long time points using rAAV6 ZFN2/1/donor at an 
MOI of 300K supplemented with rAAV6 donor at 100K (Figure 2b). For purposes of clarity 
the time course of rAAV6 donor at an MOI of 300K was left out, but the trend was similar 
(data not shown). When we supplemented with a high MOI of rAAV6 donor, which does not 
express a nuclease, we observed increased toxicity, suggesting that high a MOI of rAAV6 
itself has some degree of toxicity in HEK 293 cells. In summary, by using two AAV6 vectors 
simultaneously, gene targeting efficiencies at both early and later time points can be 
achieved that are similar to the values obtained with standard transfection techniques.
To determine whether rAAV6 delivery of the gene targeting components also stimulated 
DSB repair in a primary cell type, we used the same rAAV6 viral vectors to transduce 
immortalized fibroblasts isolated from the mouse model.20 These cells were infected with 
increasing amounts of rAAV6 ZFN2/1/donor and a dose-dependent increase in gene 
targeting was observed with a maximal frequency of 0.45% at an MOI of 500K (Figure 3a). 
Again the repair substrate was deemed limiting as a 10-fold supplementation with the 
rAAV6 donor vector increased gene targeting threefold for a targeting frequency of ~0.9% 
(Figure 3b). This value was nearly equivalent to the efficiency of gene targeting achieved by 
plasmid transfection (Figure 3b). In the time course experiments in the immortalized mouse 
fibroblast GFP* cells, we found that the percentage of GFP-positive cells did not change 
significantly over time after transfection by lipofectamine (Figures 3c and d). In contrast, we 
found that the percentage of GFP-positive cells decreased over time after infection with 
rAAV6 vectors (Figures 3c and d). The decrease in GFP-positive cells directly correlated to 
the vector MOI. In particular, the with the rAAV donor virus, suggesting that something 
about rAAV6 transduction of this cell type, rather than the in the viral vector, was causing 
some toxicity.
It is well established that proteasome inhibition increases transduction in different cell types 
in vitro and in mouse dog models in vivo.36 – 43 The mechanism by which inhibition 
increases rAAV transduction remains unknown, ever, evidence suggests that AAV particle 
trafficking to nucleus is more efficient. In addition, HDAC inhibitors also been reported to 
increase rAAV transduction by an mechanism.35 To determine whether proteasome or 
inhibitors also increase rAAV-mediated gene targeting, performed transduction experiments 
using ZFN2/1/donor in HEK 293/GFP* cell line in the presence of the bortezomib sodium 
butyrate. The results demonstrate a two- to increase in GFP +cells in the presence of either 
drug (Figure Addition of bortezomib or sodium butyrate 18 h following administration had 
no significant effect on the percentage GFP +cells in accordance with the notion that the 
drugs particle trafficking (Figure 4).36 Likewise, these drugs had no on plasmid-mediated 
gene targeting, which is consistent with earlier report testing the effect of proteasome 
inhibitors on targeting (Figure 4).35 Next, the proteasome and HDAC were added in 
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combination to the cells at the time of administration. An additive sixfold increase in 
percentage GFP +cells was noted 48 h post treatment (Figure 4). collective results suggest 
that methods to enhance rAAV transduction also result in increased rAAV-mediated gene 
ing. In addition, the additive effect noted with the drug indicates that these drugs likely 
target different steps or mechanisms to enhance rAAV transduction.
 DISCUSSION
Using homologous recombination to correct disease-causing mutations or to precisely target 
transgene insertion, theoretically, is an ideal gene therapy approach. The beneficial aspects 
of this strategy, to correct deleterious mutations thus making the cell genetically wild type, 
include the following: (1) the proper copy number of the gene is maintained, (2) endogenous 
gene regulation is preserved and (3) elimination of the concerns of the insertional activation 
of an oncogene or the insertional inactivation of a tumor suppressor gene by a viral 
integration. This strategy falls under the general category of ‘non-viral’ gene therapy 
because no viral remnants are left in the cell when the process is completed. However, low 
levels of rAAV integration can occur,44–46 however, thus far, rAAV has shown safety in 
clinical trials.47 –52 To achieve therapeutically relevant frequencies of gene targeting by 
homologous recombination in the human genome, at least two different components need to 
be introduced into cells: (1) a donor DNA molecule that serves as the repair template for the 
homologous recombination machinery and (2) a nuclease to create a site-specific genomic 
DNA DSB to stimulate homologous recombination at (or near) that site. In this work, we 
present a generally applicable context in which all of these genetic elements, as well a 
promoter and a poly-adenylation signal, can be packaged in a single AAV vector. 
Consistently, we have demonstrated that the ZFN2/Furin/T2A/ZFN1 expression cassette is 
efficiently processed to monomeric ZFNs, which are functional for gene targeting using the 
provided repair substrate. This methodology guarantees that every cell receiving ZFNs also 
receives the desired repair molecule and avoids concerns associated with multiple particle 
transduction, especially when relatively high particle numbers are necessary for efficient 
gene targeting.
In regard to nucleic acid delivery, there are several methods that can be used to deliver the 
gene targeting components. Chemical transfection and electroporation have been used in a 
variety of different cell types by multiple groups to deliver genes encoding nucleases and to 
stimulate homologous recombination.21,53,54 Although chemical- and electroporation-based 
techniques have been widely used and can accommodate large genetic payloads, they can be 
ineffective or highly toxic in primary cell types (data not shown). An alternative strategy is 
to use viral vectors to deliver the components necessary for gene targeting by homologous 
recombination. Viruses have evolved to efficiently transduce a wide variety of different 
primary cell types with minimal cytotoxic effect and have demonstrated success for gene 
delivery in vitro, ex vivo and in vivo. Deleterious clinical consequences using viral vectors 
that rely on host chromosome integration have emphasized the importance of using non-
integrating vectors for delivery. Integration-defective lentivirus vectors have been 
successfully used to deliver the gene targeting components and have demonstrated 
stimulation of gene targeting in a variety of different cell types.22,55,56 An alternative to 
using integration-defective lentivirus is to use rAAV as a viral vector for delivery, which 
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comparatively, is more efficient for transduction in vivo. Previously, high frequencies of 
gene targeting were achieved using the rAAV2 to deliver I-SceI and the donor template to 
cells either as distinct single-strand or as self-complementary genomes.5,29,57 An inherent 
problem with these previous approaches is the possibility of single vector transduction, for 
instance some cells are transduced by the donor only vector, which is inefficient for gene 
targeting (Supplementary Figure S1). In addition, transduction only by the endonuclease 
vector is a more serious problem as induced DSBs are most often repaired by non-
homologous end joining, which is associated with unwanted deletions and mutations. In this 
work, we eliminated these concerns by engineering a single AAV6 vector that effectively 
delivers both the endonuclease and repair substrate into mouse and human cells to stimulate 
ZFN-mediated gene targeting.
Regarding the efficiency of gene targeting, we found that titrating the amount of AAV6 used 
to transduce cells was important for maximizing the frequency of gene correction. For 
instance, in both cell types the number of GFP +cells directly correlated to the amount of 
AAV-ZFN2/1/donor used for infection. As seen with most ZFN-mediated targeting 
experiments, the efficiency of the gene correction decreased to a stable level over time.35 
This result herein, which was more obvious in the human cell line (Figure 2), could be 
explained in several ways, as well as a by a combination of effects including: (i) ZFN 
toxicity and (ii) rAAV-induced toxicity at high particle titers. This trend, a loss of GFP +cells 
over time, was also noted for the transfection experiments in the human cells (Figure 2). In 
addition to titration of the AAV-ZFN2/1/donor cassette, we also noted that the use of 
additional AAV-donor particles increased gene correction in both cell types about threefold. 
This result suggests that the amount of repair DNA is limiting in these gene-targeting 
experiments. However, too much AAV-donor actually decreased the gene targeting 
efficiency, an effect we speculate is due to the inherent problem with co-transduction 
strategies: AAV vector competition (Figure 2b). The data herein demonstrate that, in general, 
increased amounts of the AAV-ZFN 2/1/donor vector resulted in increased targeting and that 
supplemental AAV-donor transduction further increases rAAV transduction until, perhaps, 
particle competition becomes inhibitory. This interpretation is further supported by no 
inhibitory effect on gene targeting using AAV-donor vector supplementation in the mouse 
model derived cells, which are not efficiently transduced by AAV6.
Our finding also highlights the importance of the intracellular metabolism of the AAV6 
vector and noted that the frequency of targeting was increased 2- to threefold in the presence 
of either proteasome or HDAC inhibitors. In previous work, we have demonstrated that 
proteasome inhibition increases rAAV trans-duction in cell culture and in small and large 
animal models.36,37 Although the mechanism by which proteasome inhibition increases 
rAAV transduction remains unknown, it appears to elicit its effect on the nuclear trafficking 
of rAAV particles.36 Consistently, we noticed no effect of the proteasome inhibitor when the 
drug was administered 18 h post transduction or on transfected plasmid DNA. Only a few 
reports demonstrate increased rAAV vector transduction in the presence of sodium butyrate 
and again, the mechanism by which this occurs remains elusive.58 Similar to the results with 
the proteasome inhibitor, sodium butyrate did not alter gene targeting levels when added 18 
h post transduction or when using transfected plasmid components. Thus, the enhancement 
of gene targeting by either of the drug inhibitors is specific to the AAV vector and is likely 
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elicited at the level of rAAV particle trafficking to, and perhaps, within the nucleus. Given 
this, the demonstration of an additive effect on gene targeting in the presence of both drugs 
is interesting, and suggests that at least partially different AAV transduction pathways exist 
and are influenced separately by each drug. This observation is currently under further 
investigation.
The objective of this work was to devise and validate a safer and more efficient rAAV-
mediated gene targeting strategy at 2 levels: (i) a universal single rAAV vector capable of 
inducing a specific DNA DSB and repairing it with a provided DNA substrate via HR and 
(ii) optimization of rAAV transduction conditions using clinical drugs that also, secondarily, 
result in increased targeted gene repair. Both of these levels of optimization are applicable to 
dividing primary cell cultures as well as particular tissues in vivo. These enhancements 
become particularly important for transduction of less permissive cells or a great number of 
cells (that is, CD34 +cells or the liver, respectively), in which instances of multiple vector 
transduction of a single cell are unlikely. The transition of these vector enhancements to ex 
vivo gene targeting is underway and was the rationale for using the AAV6 capsid herein, 
which is generally efficient for stem cell transduction (Ellis et al., submitted). However, 
several complications exist preventing simple data interpretation in these experiments. For 
example, our unpublished data of rAAV-mediated gene targeting in mouse mesenchymal 
stem cells reveal that gene correction does occur, however, it is not clear if naïve 
mesenchymal stem cells, or partially differentiated mesenchymal stem cell derivatives, 
undergo the event. To further complicate result interpretation, a significant amount of 
toxicity was observed posing the question of whether naïve mesenchymal stem cells would 
rather tolerate and repair a DSB or induce apoptosis, a decision that likely reflects the 
recognition specificity of the endonuclease among other factors. Currently, we are in the 
process of elucidating the DSB repair capacity of multiple primary cell types at varying 
levels of differentiation.
In summary, we demonstrate for the first time ZFN-mediated gene targeting using rAAV 
transduction in both human and mouse cells. To do this, we engineered a universal vector 
format to include all of the necessary components in a single vector by using a 2A peptide 
sequence, which is significant because the use of an internal ribosome entry site sequence or 
multiple promoters would have put the genome above the packaging restriction size for AAV 
capsids. AAV vectors based on this format eliminate the associated safety concerns of a 
multiple transduction strategy and are applicable to both in vitro and in vivo applications.59 
In addition, this is the first report to demonstrate that Food and Drug Administration-
approved drugs can be used solely, or in combination, to increase AAV-mediated gene 
targeting up to sixfold. These collective enhancements on rAAV vector design and 
application decrease the relatively high required vector dose for safe and efficient gene 
targeting. However, several concerns remain, such as the efficiency of stem/dividing cells to 
undergo homologous recombination (instead of apoptosis), that should be addressed before 
the transition of technology for human therapy.
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 MATERIALS AND METHODS
 DNA manipulations and cloning
 AAV constructs—The ZFN1/2/donor construct was made by PCR of the UbC promoter 
from pUB6/V5-His A (Invitrogen, Carlsbad, CA, USA) in which the 5′-primer hybridized 
with the 5′-end of the UbC and contained a NotI site (5′-
AGGACCGCGGCCGCGGCCTCCGCGCCGGGTTTTGG-3′) and the 3′-primer hybridized 
with he 3′ end of the UbC promoter and contained a BamHI site (5′-
AGGACCGGATCCGAGCTCGGTACCAAGCTTCGT-3′). This PCR fragment was then 
digested with NotI and BamHI and ligated into the pAAVMCS (Stratagene, La Jolla, CA, 
USA) construct digested with BamHI and partially digested with NotI. This construct 
already contained the GFP-ZFN2 2A GFPZFN1(ref. 37)-eGFP fragment, which was 
generated using by PCR/cloning of a previously described furin (RNRR) T2A linker 
sequence using the following primer sequences: M480-A 5′-AGGCCCTGCAGGGGGG 
CCGGGGTTCTCCTCCACGTCGCCGCAGGTCAGCAGGCTGCCCCTG-3′, M480-B 5′-
GTCAGCAGGCTGCCCCTGCCCTCGCCGCTGCCGCTGCGGCGCTTGCGAAAG 
TTTATCTCGCCGTTATT-3′, M480-C 5′-AGGCCTCGAGCTAAAAGTTTATCTCGC 
CGTTATT-3′, SNP21-F 5′-TCGATCGGATCCTAGGGATAACAGGGTAATATGGA 
CTACAAAGACGATGAC-3′, SNP38-F 5′-TCGATCCCTGCAGGCGACTACAAAGA 
CGATGAC-3′ (details available upon request.33 Briefly, the GFP-ZFN2 2A GFP-
ZFN1(ref. 37)-eGFP was cloned in using BamHI and XhoI sites of the pAAVMCS vector. The 
donor construct was made by digestion of a plasmid containing a truncated form of eGFP 
(37-eGFP) discussed previously, and ligated into the multiple cloning site of the pAAVMCS 
vector with BamHI and XhoI.
 Cell culture
Cell culture experiments were performed in either stably transfected HEK 293 cells 
containing the GFP gene targeting construct described previously5 or in 3T3 cells derived 
from a transgenic mouse containing the GFP gene targeting construct also described 
previously20. As previously reported, the GFP gene targeting construct contains a 35 
nucleotide insertion within the egfp coding sequence: 5′-CGACGGCAACTACAAG 
ACCTAAGCTCTCGAGATTACCCTGTTATCCCTAAGCTTCGCGCCGAGGTGAAGT-3′ 
(italics are egfp coding sequence flanking the insertion sequence, the I-SceI site is 
underlined). The cells were cultured in Dulbecco’s modified Eagle’s medium (Media Tech, 
Manassas, VA, USA) supplemented with 10% bovine growth serum (Hyclone, Logan, UT, 
USA), 2 mM L-glutamine, 100 IU ml−1 penicillin and 100 mg ml−1 streptomycin. The 
cultures were grown in a humidified incubator at 37 °C with 5% CO2.
 Western blot
About 100 000 HEK 293T cells were calcium phosphate transfected with 100 ng of the ITR-
UBC-ZFN2/1/donor-ITR, LTR-UBC-ZFN2/1/donor-LTR, LTR-UBC-ZFN2-LTR or LTR-
UBC-ZFN1-LTR construct in triplicate. Transfection efficiency was about 40% determined 
by separate transfection with eGFP and analyzed by flow cytometry on a fluorescence-
activated cell sorting Calibur (Becton-Dickerson, San Jose, CA, USA). Cells were harvested 
at 48 h post transfection and triplicates were combined. Equal amounts of total lysates were 
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subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, wet transferred to 
polyvinylidene difluoride membranes and incubated with specific antibodies. ZFNs were 
detected with an anti-Flag M2 monoclonal antibody (1:10 000, Sigma-Aldrich, St Louis, 
MO, USA), and β-actin was detected with a rabbit anti-actin antibody (1:5 000, Sigma-
Aldrich). The blots were then incubated with horseradish peroxidase-conjugated secondary 
antibodies and visualized using western blotting luminal reagent (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA).
 Virus production
 rAAV production—Single-strand rAAV was generated using the triple transfection 
method60 in plated HEK 293T cells. All transfections for rAAV6 production contained an 
adenovirus helper plasmid (pXX680) and the pXR6 plasmid containing the AAV Rep2 and 
capsid six genes.60 In addition, a third plasmid was included that contains the desired AAV 
genome flanked by the inverted terminal repeats of AAV2. For the experiments herein, two 
such plasmids were used, pZFN2/1/donor and pdonor, which are described in the DNA 
manipulations and cloning section above. Three days post transfection, nuclei were purified 
from harvested cells, lysed by sonication and applied to a cesium chloride gradient as 
described.59,60 Following an overnight spin at 65 000 r.p.m, gradient fractions were 
investigated for AAV particles containing the desired genome. rAAV peak fractions were 
then pooled, dialyzed in phosphate-buffered saline and stored at −80 °C. The number of 
genome containing particles was determined by quantitative PCR using the following GFP 
primer set: forward primer, 5′-AGCAGCACGACTTCTTCAAGTCC-3′ and the reverse 
primer 5′-TGTAGTTGTACTCCAGCTTGTGCC-3′.
 Gene targeting by infection or lipofection
For all gene targeting experiments, at hour 0, 10 000 cells per well were split into a 24-well 
plate in 500 μl of media and cells were infected at the indicated MOI. For lipofection 
experiments, Lipofectamine 2000 (Invitrogen) was added to the cells with either 800 ng 
eGFP (transfection control) or 100 ng of ZFN2/1/D and 700 ng of donor (a typical amount 
and ratio for optimum targeting frequency). The cells were then maintained in the 37 °C 
incubator until time of analysis. If a time course was done,  of the cells were analyzed for 
GFP expression and  of the cells were replated for further expansion. For gene targeting 
experiments, media were changed at hour 6. For the gene targeting experiments with the 
proteasome inhibitor MG-132 (Sigma-Aldrich), drug was resuspended in dimethyl sulfoxide 
for a stock concentration of 1 mM and was then added to each well to the indicated final 
concentration at the time of infection. In the case of the MG-132 lipofection experiments, 
drug was not added until hour 2 of the experiment. In all MG-132 experiments the media 
were changed after 4 h of exposure and drug was not added back.
 Measurement of gene targeting using the GFP system
For all gene-targeting experiments, both with HEK 293 cells and 3T3 cells, the cells were 
harvested and then analyzed on a fluorescence-activated cell sorting Calibur (Becton-
Dickerson) for GFP expression. Each condition was analyzed in triplicate. Typical 
transfection efficiency by Lipofectamine 2000 was 50–70%.
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Schematic representations of the genomic contents of AAV6 ZFN2/1/D and AAV6 donor. 
(a) The genome of the AAV6 viral vector ZFN2/1/D, which contains DNA encoding two 
GFP ZFNs separated by a 2A peptide driven by the ubiquitin C promoter, and includes the 
eGFP gene truncated at nucleotide 37 as a donor substrate in gene targeting by homologous 
recombination. (b) The genome of the AAV6 viral vector donor, which contains the same 
truncated, non-functional form of eGFP as in (a), and is driven by the cytomegalovirus 
promoter. (c) Western blot from calcium phosphate transfection of ZFN2/1/D construct in 
the AAV backbone (lane 1), the ZFN2/1/donor* construct in a lentiviral backbone (lane 2), 
the ZFN2 construct in a lentiviral backbone (lane 3) and the ZFN1 construct in a lentiviral 
backbone (lane 4). Note that most of the protein from lane 1 is present at the monomeric 
weight (37 kD marker).
Ellis et al. Page 15














ZFN-mediated gene targeting in HEK 293 cells delivered by AAV6. (a) Gene targeting in 
HEK 293 cells with increasing MOIs of AAV6 ZFN 2/1/D virus, analyzed on day 3 for GFP 
by flow cytometry. (b) Gene targeting in HEK 293 cells with increasing MOIs of AAV6 
donor virus and a constant MOI of 300K for the AAV6 ZFN 2/1/D virus, analyzed on day 3 
for GFP by flow cytometry. (c) Kinetic analysis of gene targeting in HEK 293 cells with 
increasing MOIs of AAV6 ZFN 2/1/D virus analyzed by flow cytometry at the indicated 
time points post infection. (d) Gene targeting in HEK 293 cells with increasing MOIs of 
AAV6 donor virus and a constant MOI of 300K for the AAV6 ZFN 2/1/D virus, analyzed at 
the indicated time points for GFP by flow cytometry. *Significantly different compared with 
the lipofected sample. n = 3, P < 0.05 (for c and d: only evaluated at the last time point 
between lipofection and the infected population closest to the lipofected value).
Ellis et al. Page 16














ZFN-mediated gene targeting in Rosa 26 3T3 cells delivered by rAAV6. (a) Gene targeting 
in Rosa 26 3T3 cells with increasing MOIs of rAAV6 ZFN 2/1/D virus, analyzed on day 3 
for GFP by flow cytometry. (b) Gene targeting in Rosa 26 3T3 cells with increasing MOIs of 
rAAV6 donor virus and a constant MOI of 300K for the rAAV6 ZFN 2/1/D virus, analyzed 
on day 3 for GFP by flow cytometry. (c) Kinetic analysis of gene targeting in Rosa 26 3T3 
cells with increasing MOIs of rAAV6 ZFN 2/1/D virus, analyzed for GFP by flow 
cytometry. (d) Kinetic analysis of gene targeting in Rosa 26 3T3 cells with increasing MOIs 
of rAAV6 donor virus and a constant MOI of 300K for the rAAV6 ZFN 2/1/D virus. GFP-
positive cells were then analyzed at the indicated time points by flow 
cytometry.*Significantly different compared with the lipofected sample. n = 3, P < 0.05 (for 
c and d: only evaluated at the last time point between lipofection and the infected population 
closest to the lipofected value).
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Enhancement of gene targeting using Food and Drug Administration-approved drugs. HEK 
293 cells were transduced with rAAV6 ZFN 2/1/donor at 100 000 viral genomes per cell. At 
the time of vector addition (co-administered) or 18 h post vector addition, cells were treated 
with the indicated drug (bortezomib 2 μM; sodium butyrate 1.5 μM). Two days following 
vector addition, cells were harvested and GFP +cells were quantitated by flow cytometry. 
The value determined in the presence of the drug was divided by the value determined in the 
absence of the drug and the data are presented as a fold change. Plasmid experiments relied 
on the same general strategy, however, in these cases the drug was given 4 h pos-
transfection.
Ellis et al. Page 18
Gene Ther. Author manuscript; available in PMC 2016 July 22.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
